Heart biopsy to check for amyloidosis during pacemaker placement
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This research study checks a small sample of heart tissue during pacemaker or defibrillator placement to see if amyloidosis, a condition where abnormal proteins build up in organs, is present. It aims to find amyloidosis earlier so treatment can start sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 or older, or between 50 and 64 with a family history or genetic risk of hereditary ATTR amyloidosis.
- You are scheduled to have a pacemaker, CRT device, or ICD implanted.
- You are willing to follow all study procedures and be available for the follow-up period.
- You have at least one heart-related or other condition or sign that might be linked to amyloidosis (like heart failure, unexplained kidney problems, or carpal tunnel syndrome).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to find, describe, and track people with cardiac amyloidosis over time. It uses MRI scans and other tests to better understand the condition, which may help guide future treatment.
This study uses signals from a pacemaker or defibrillator to help detect a condition called cardiac amyloidosis, where abnormal proteins build up in the heart. It may help diagnose this condition earlier without extra tests.
This trial tests whether setting your pacemaker to a slightly faster minimum heart rate (the 'lower rate') can improve your heart function and symptoms. It might help by making your heart beat more efficiently, potentially reducing fatigue and shortness of breath.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This study uses special heart tests (AI-ECG and CT scan) to look for a hidden condition called cardiac amyloidosis, which can affect people with atrial fibrillation. Finding it early may help guide treatment and improve outcomes.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.